By discovering the link between TP53 mutation and IL4I1/IDO1/AHR pathway, we show strong evidence of Δ133p53α R273H clinical relevance in mutant TP53 glioblastoma development and aggressiveness, and as a potential therapeutic target and biomarker. Here, IDO1 is linked to glioblastoma.